NanoFUSE Biologics has developed a groundbreaking technology that combines FDA-approved synthetic bioactive ceramic 45S5 bioglass with demineralized bone matrix (DBM). This unique combination is designed to enhance bone regeneration and healing, making it a significant advancement in the field of osteobiologics. The product is moldable and customizable, allowing for versatile applications in various clinical settings. Additionally, it features a patented design and manufacturing process, ensuring high-quality standards and efficacy. The technology has a proven clinical track record and is available in multiple forms, with a five-year sterile packed shelf life, which adds to its practicality for medical use.

The advantages of NanoFUSE's technology extend beyond its innovative composition. The product is anti-microbial, which helps reduce the risk of infection during the healing process. Since receiving FDA approval on February 9, 2015, NanoFUSE Biologics has positioned itself as a leader in the osteobiologics market, providing solutions that are not only effective but also safe for patients. The combination of these features underscores the company's commitment to advancing bone healing technologies and improving patient outcomes in orthopedic and spinal surgeries.

United States

Nanofuse is a regenerative therapeutic that has the properties of replacing or "regenerating" human bone cells to form normal bone.

NanoFUSE Biologics products contain the only bioactive glass that is FDA-Cleared to be combined with demineralized bone matrix (DBM). The regenerative efficacy comes from the osteoinductivity of the DBM component plus the osteopromotivity of the bioactive glass.

Bioactive glass has been clinically proven for over 30 years but only until now has NanoFUSE Biologics used bioactive glass to create a revolutionary and patented regenerative therapeutic.

NanoFUSE Biologics

Company Details